Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies.
The sensitizing ability of 100% normobaric oxygen was investigated in a mouse mammary carcinoma (CaNT) using a variety of fractionated regimens. Both regrowth delay and local control were used as assays of tumor response. With both assays, there was a similar and significant increase in radiosensitivity for all fractionated schedules. Enhancement ratios ranged from 1.24 to 1.45, the highest increase being observed with a 30 fraction schedule given in an overall time of 6 weeks. Thus, in CaNT tumors normobaric oxygen is a far more efficient radiosensitizer in fractionated treatments than the oxygen-mimetic compound misonidazole; an oxygen effect being observed at doses per fraction as low as 1.8 Gy. These results suggest strongly that normobaric gases could play an important role in the clinical management of tumors where hypoxia may limit the outcome of radiotherapy.
Rojas
A
A
CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK.
Carl
U
U
Reghebi
K
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D000818:Animals; D002245:Carbon Dioxide / Q000627:therapeutic use; D015687:Cell Hypoxia / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy*; D051379:Mice; D009368:Neoplasm Transplantation; D010100:Oxygen / Q000627:therapeutic use*; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D011838:Radiation-Sensitizing Agents; D002245:Carbon Dioxide; C011700:carbogen; D010100:Oxygen